Trial Profile
CAALL-F01: National Protocol for the Treatment of Childhood and Adolescent Acute Lymphoblastic Leukemia (LAL)
Status:
Not stated
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2017
Price :
$35
*
At a glance
- Drugs Pegaspargase (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms CAALL F01
- 06 Oct 2017 New trial record